Three Lessons From the 'Negative' ZEUS and HORIZON Trials

03 Nov 2026 0 comments

Before the presentations at the upcoming AHA, there are already lessons for clinicians on the null findings of the anti-inflammatory and Lp(a)-lowering ZEUS and HORIZON drug trials, writes John Mandrola, MD.
theheart.org on Medscape

Source: Medscape Neurology Published 03 Nov 2026 Imported 03 Nov 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment